CAR T

Lixia Wang1,2,3, Gang Jin1,2,3, Qiuping Zhou1,2,3

  • 1State Key Laboratory of Molecular Oncology, Beijing Key Laboratory for Immunological Research on Chronic Diseases, School of Medicine, Institute for Immunology, Tsinghua University, Beijing, China.

概括

研究人员通过抑制BCOR和ZC3H12A.A.来诱导仿真抗原受体 (CAR) T细胞进入一种类似不朽和功能状态 (TIF). 这些重新编程的CARTIF细胞表现出增强的干性和持久性,从而在体内产生优异的长期抗瘤作用.